Skip to main content

Supporting Clinical Development of AUTX-703 in Relapsed/Refractory AML and MDS

Project Term
TBD

Project Summary

Auron Therapeutics is a platform-powered company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease. Auron pioneered its AURIGIN platform, which uses AI and machine learning to compare cell states and identify novel drug targets, optimal development models, and biomarkers to facilitate proper patient selection, ultimately accelerating the development of effective and durable therapies.

Lay Abstract

Program

Therapy Acceleration Program

Grant Subprogram

Biotechnology Accelerator

The Leukemia & Lymphoma Society (LLS) is now Blood Cancer United. Learn more.